Opioid Overdose - Pipeline Insight, 2024

This “Opioid Overdose- Pipeline Insight, 2024” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Opioid Overdose pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Opioid Overdose: Understanding

Opioid Overdose: Overview

Opioid overdose is a serious and potentially fatal condition resulting from the excessive consumption of opioid drugs, which include prescription medications like oxycodone and morphine, as well as illicit substances like heroin. Opioids act on the central nervous system (CNS) to relieve pain, but in high doses, they can significantly depress respiratory function and other vital processes. The rising incidence of opioid overdoses has become a critical public health issue, exacerbated by the increased availability of both prescription and illegal opioids.

The hallmark signs of opioid overdose include pinpoint pupils, unconsciousness, and respiratory depression, which can manifest as slow, shallow, or absent breathing. Additional symptoms may include cyanosis (a bluish tint to the lips and skin), limp body, pale or clammy face, vomiting, gurgling sounds, and an inability to speak or awaken. These symptoms indicate a medical emergency, requiring immediate intervention to prevent brain damage or death due to hypoxia (lack of oxygen).

Opioid overdose occurs when the quantity of opioids in the system overwhelms the body's ability to metabolize and eliminate them, leading to toxic levels that impair vital functions. Opioids exert their effects by binding to specific receptors in the brain and other tissues. In overdose situations, these drugs excessively stimulate the mu-opioid receptors, leading to severe CNS depression. This affects the brainstem's control of autonomic functions, particularly respiration. The resulting hypoventilation causes carbon dioxide to accumulate and oxygen levels to drop, potentially leading to respiratory arrest, hypoxic brain injury, and death.

Diagnosis of opioid overdose is primarily clinical, based on the observed signs and symptoms and the patient’s history. Rapid diagnosis is crucial to effective treatment. Confirmatory testing may include toxicology screens to identify the specific opioid involved. The primary treatment for opioid overdose is the administration of naloxone, an opioid antagonist that reverses the effects of opioid toxicity by competitively binding to the opioid receptors. Naloxone can be administered intravenously, intramuscularly, or intranasally and often results in rapid improvement in respiratory function. Supportive care, including ventilation support, may be necessary until the effects of the opioids have worn off. Prevention strategies include education on safe opioid use, access to naloxone, and substance use disorder treatment programs.

"Opioid Overdose- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Opioid Overdose pipeline landscape is provided which includes the disease overview and Opioid Overdose treatment guidelines. The assessment part of the report embraces, in depth Opioid Overdose commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Opioid Overdose collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Opioid Overdose R&D. The therapies under development are focused on novel approaches to treat/improve Opioid Overdose.

Opioid Overdose Emerging Drugs Chapters

This segment of the Opioid Overdose report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Opioid Overdose Emerging Drugs

ENA-001: Enalare Therapeutics Inc.

ENA-001, is a patent-protected new chemical entity (NCE) beginning additional clinical trials during the fourth quarter of 2021. With its novel mechanism-of-action and demonstrated safety and efficacy, it holds the potential of dramatically improving the lives of those impacted by several life threatening conditions including drug overdose, post-operative respiratory depression, and apnea of prematurity. ENA-001 offer new treatment options for physicians, emergency responders, and care-givers addressing respiratory depression in multiple settings. BARDA and Enalare Therapeutics entered into a new partnership to develop ENA-001 in an intramuscular (IM) formulation for use as an emergency treatment for opioid overdose. Currently, the drug is in Phase I stage of its development for the treatment of opioid use disorder and opioid disorder.

Opioid Overdose: Therapeutic Assessment

This segment of the report provides insights about the different Opioid Overdose drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Opioid Overdose

• There are approx. 6+ key companies which are developing the therapies for Opioid Overdose. The companies which have their Opioid Overdose drug candidates in the most advanced stage, i.e. phase I include, Enalare Therapeutics Inc.

Phases

DelveInsight’s report covers around 6+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Opioid Overdose pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Opioid Overdose: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Opioid Overdose therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Opioid Overdose drugs.

Opioid Overdose Report Insights

• Opioid Overdose Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Opioid Overdose Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Opioid Overdose drugs?
• How many Opioid Overdose drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Opioid Overdose?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Opioid Overdose therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Opioid Overdose and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Enalare Therapeutics Inc.
• Avior
• Nasus Pharma

Key Products

• ENA-001
• ANV 103
• NS-001

This product will be delivered within 2 business days.